Ralph Andre - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ralph Andre

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Brain : a Journal of Neurology|January 25, 2014

HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulationUlrike Träger, Ralph Andre, Nayana Lahiri, et al.

The Journal of Experimental Medicine|July 16, 2008

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseMaria Björkqvist, Edward J Wild, Jenny Thiele, et al.

British Journal of Clinical Pharmacology|September 17, 2014

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Brain : a Journal of Neurology|January 25, 2014

HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulationUlrike Träger, Ralph Andre, Nayana Lahiri, et al.

The Journal of Experimental Medicine|July 16, 2008

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseMaria Björkqvist, Edward J Wild, Jenny Thiele, et al.

British Journal of Clinical Pharmacology|September 17, 2014

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.

Pageof 4